Get started
Author

Daniele Xavier Assad

Observed names: D. Assad-Suzuki, D. X. Assad, D., AssadSuzuki, D.X. Assad, DANIELE XAVIER ASSAD, Daniele Assad, Daniele Assad Suzuki, Daniele Assad-Suzuki, Daniele Assad‐Suzuki
Observed institutions: Universidade de Brasília, Richmond University Medical Center, Centro Brasileiro de Estudos em Dermatologia, University Center of Brasília, Instituto Nacional de Câncer - INCA, Hospital Sírio-Libanês, Sociedade Brasileira de Oncologia Clínica
ORCID: 0000-0001-9722-0904
Observed ORCID: 0000-0001-9722-0904
OpenAlex ID: A5071166698
Salivary biomarkers in the diagnosis of breast cancer: A review
2016 · Elisa Cançado Porto-Mascarenhas, Daniele Xavier Assad, et al. · Critical Reviews in Oncology/Hematology · 96
In vivo and in vitro effects of curcumin on head and neck carcinoma: a systematic review
2016 · Gabriel Álvares Borges, Daniela Fortunato Rêgo, et al. · Journal of Oral Pathology and Medicine · 50
PDF
Salivary metabolites to detect patients with cancer: a systematic review
2020 · Daniele Xavier Assad, Elisa Cançado Porto Mascarenhas, et al. · International Journal of Clinical Oncology · 37
Deglutition disorders as a consequence of head and neck cancer therapies: a systematic review and meta-analysis
2019 · Isabela Porto de Toledo, Leticia Lopes Quirino Pantoja, et al. · Supportive Care in Cancer · 31
Germline molecular data in hereditary breast cancer in Brazil: Lessons from a large single-center analysis
2021 · Renata Lazari Sandoval, Ana Carolina Rathsam Leite, et al. · PLoS ONE · 30
PDF
Using an Untargeted Metabolomics Approach to Identify Salivary Metabolites in Women with Breast Cancer
2020 · Daniele Xavier Assad, Ana Carolina Acevedo, et al. · Metabolites · 28
PDF
Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study
2025 · Matheus de Oliveira Andrade, Isabella Gonçalves Gutierres, et al. · The Breast · 25
PDF
Worldwide prevalence of PI3K-AKT-mTOR pathway mutations in head and neck cancer: A systematic review and meta-analysis
2021 · Adriana Castelo de Moura, Daniele Xavier Assad, et al. · Critical Reviews in Oncology/Hematology · 24
Additive cytotoxic effects of radiation and mTOR inhibitors in a cervical cancer cell line
2017 · Daniele Xavier Assad, Gabriel Alvares Borges, et al. · Pathology - Research and Practice · 22
Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil
2023 · Marcello Moro Queiroz, Karina Perez Sacardo, et al. · Cancer Treatment and Research Communications · 20
Potential impact of mTOR inhibitors on cervical squamous cell carcinoma: A systematic review
2016 · Daniele Xavier Assad, Silvia Taveira Elias, et al. · Oncology Letters · 20
PDF
Correlation between salivary and serum CA15‑3 concentrations in patients with breast cancer
2020 · Daniele Assad, Elisa Mascarenhas, et al. · Molecular and Clinical Oncology · 19
Linfoma Não-Hodgkin de Alto Grau - Revisão da Literatura
2008 · Luiz Henrique de Lima Araújo, Ana Paula Ornellas de Souza Victorino, et al. · Revista Brasileira de Cancerologia · 16
PDF
Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer
2024 · Renata Colombo Bonadio, Isadora Martins de Sousa, et al. · npj Breast Cancer · 10
PDF
Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study
2022 · Leandro Jonata Carvalho Oliveira, Thais Baccili Cury Megid, et al. · Therapeutic Advances in Medical Oncology · 10
Breast oncology and the COVID-19 pandemic: Recommendations from the Brazilian Society of Clinical Oncology (SBOC)
2019 · Gilberto Luiz da Silva Amorim, Daniele Xavier Assad, et al. · Brazilian Journal of Oncology · 10
Breast and gynecologic cancers as a Brazilian health priority
2023 · Angélica Nogueira-Rodrigues, Daniela Dornelles Rosa, et al. · Revista da Associação Médica Brasileira · 9
PDF
Single nucleotide polymorphisms to predict acute radiation dermatitis in breast cancer patients: A systematic review and meta-analysis
2022 · Beatriz Regina Lima de Aguiar, Elaine Barros Ferreira, et al. · Critical Reviews in Oncology/Hematology · 7
Pathologic complete response rates of patients with ER-low/HER2-negative breast cancer treated with neoadjuvant pembrolizumab plus chemotherapy in the neo-real study
2025 · Renata Colombo Bonadio, Monique Celeste Tavares, et al. · Breast Cancer Research and Treatment · 6
Real-World Evidence of Ribociclib Plus Aromatase Inhibitors as First-Line Treatment in Advanced Breast Cancer: The BrasiLEEira Study
2024 · Daniele Assad Suzuki, Alessandra Menezes Morelle, et al. · JCO Global Oncology · 6
PDF
Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: A GBECAM multicenter retrospective study.
2022 · Leandro Carvalho Oliveira, Thais Baccili Cury Megid, et al. · Journal of Clinical Oncology · 4
Prediction of pathologic complete response to chemoimmunotherapy in triple-negative breast cancer using tumor-infiltrating lymphocytes: Exploiting cutoff values.
2024 · ROMUALDO BARROSO-SOUSA, Isadora Martins de Sousa, et al. · Journal of Clinical Oncology · 3
PDF
Cancer outcomes from a real-world cohort of patients eligible for adjuvant CDK4/6 inhibitors but without genomic risk for chemotherapy: A GBECAM multicenter retrospective study.
2024 · Leandro Jonata Carvalho Oliveira, Daniela Dornelles Rosa, et al. · Journal of Clinical Oncology · 3
Neoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123
2026 · Mariana Carvalho Gouveia, Romualdo Barroso-Sousa, et al. · npj Breast Cancer · 2
PDF
Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study
2025 · S. Kuemmel, K.H. Jung, et al. · ESMO Open · 2
Works count: 85
Citation count: 510
H-index: 13
I10-index: 16
Year
Topic
Type